Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment

Table 4 Secondary endpoints

	T0 (n = 57)	T3 (n = 57)	T6 (n = 50)	T9 (n = 36)	T12 (n = 20)	T15 (n = 13)	T18 (n = 7)
HIT-6 score	63.94 ± 6.91	63.6 ± 6.89	62.14 ± 8.06	61.94 ± 8.13	58.55 ± 9.40*	55.7 ± 9.24**	52.28 ± 8.69**
VAS score	7.98 ± 1.26	6.98 ± 1.57**	6.01 ± 1.89**	5.19 ± 1.82**	5.14 ± 1.61**	4.69 ± 1.75**	4.25 ± 1.48**
SF-36 Mental	48.30 ± 21.68	50.41 ± 22.50	51.71 ± 22.35	52.82 ± 23.44	59.41 ± 21.16	67.8 ± 16.8**	73.90 ± 20.26*
SF-36 Physical	46.35 ± 18.90	46.85 ± 20.21	49.17 ± 19.90	48.94 ± 19.80	52.58 ± 24.69	62.11 ± 23.5*	70.18 ± 23.22*
ZUNG-A	41.27 ± 10.26	20.69 ± 9.82	40.76 ± 10.39	39.43 ± 9.74	37.48 ± 9.43	35.08 ± 7.11*	34 ± 6.11
ZUNG-D	42.95 ± 11.25	42.80 ± 11.31	43.4 ± 12.08	41.32 ± 10.03	38.23 ± 10.39	35.69 ± 7.82	37.14 ± 7.65

*P < 0.05; **P < =0.01 ANOVA followed by Wilcoxon test for paired data versus T0

ISSN: 1129-2377